The Low Endotoxin (LER) and Lipopolysaccharide Recovery (LLR) phenomena have been debated as a Limulus Ameobocyte Lysate (LAL) test validity issue peculiar to therapeutic monoclonal antibodies for over three years. The FDA... read more